文献速递临床试验与 GCP流行病学与生物统计

羟氯喹预防医护人员COVID-19病毒感染:随机对照试验方案结构化摘要

Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-06-03

该试验为单中心、双盲、1:1 安慰剂对照随机试验,计划纳入 282 名伊朗 Arash 医院频繁接触患者且每周至少 3 班的工作人员,比较羟氯喹 200 mg 片(每日两片、每周一次、持续 1 至 3 个月)与安慰剂预防 COVID-19 病毒感染的效果,主要结局为 PCR 确诊感染。

要点

  • 主要结局为试验期间至末次给药后 1 个月内 PCR 确诊的 COVID-19 感染。
  • 干预为羟氯喹 200 mg 片每日两片、每周一次,持续 1 至 3 个月。
  • 采用区组随机(区组大小 6)、分配隐藏与双盲,独立统计人员分析数据。

核心结论

  • 方案旨在比较羟氯喹与安慰剂预防医护人员 COVID-19 病毒感染的效果。
  • 主要结局为 PCR 确诊的 COVID-19 病毒感染。

研究设计与样本

  • 单中心、两臂、双盲、1:1 随机安慰剂对照试验。
  • 计划随机 282 名参与者,羟氯喹组与安慰剂组各 141 名。
  • 研究对象为伊朗 Arash 医院接触患者且每周至少 3 班并同意参与的治疗人员。
  • 采用区组随机,区组大小为 6,由独立研究者用 Stata 15 软件生成。

关键数值与推荐

  • 干预组使用羟氯喹 200 mg 片(Amin Pharmaceutical),对照组使用同厂外观与味道相似的安慰剂。
  • 给药方案为每日两片、每周一次,持续 1 至 3 个月,依据德黑兰新冠疫情持续时间确定。
  • 主要结局测量时段为试验期间至末次给药后 1 个月内发生的任何感染。
  • 排除标准包括既往 COVID-19 感染史、近两个月发热恶心呼吸困难肌痛等症状、基础疾病史、羟氯喹过敏及 G6PD 酶缺乏。

临床怎么用

  • 该方案为医护人员药物预防研究设计,尚不提供临床用药推荐。

局限性

  • 单中心设计,结果外推需谨慎。
  • 给药持续时间 1 至 3 个月依据疫情持续时间确定,存在可变性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Comparison of the effect of hydroxychloroquine with placebo to prevent infection from the COVID -19 virus among healthcare professionals TRIAL DESIGN: Single centre, 2-arm, double-blind randomised (ratio 1:1) placebo-controlled trial PARTICIPANTS: Treatment staff who are in contact with patients and have at least 3 shifts a week in Arash hospital affiliated with Tehran University of Medical Sciences, in Iran and who consent to participate in the study. Exclusion criteria include: History of COVID -19 virus infection, clinical symptoms such as fever, nausea, dyspnea and myalgia in the past two months, history of underlying diseases hypersensitivity to hydroxychloroquine and G6PD enzyme deficiency. INTERVENTION AND COMPARATOR: Intervention group: Hydroxychloroquine 200 mg tablet of Amin Pharmaceutical. CONTROL GROUP: placebo which is completely similar in form and taste to 200 mg hydroxychloroquine tablet and is manufactured by the same factory (Amin Pharmacy). The dosage is two tablets daily, once a week for one to three months (based on the duration of the Coronavirus epidemic in Tehran). MAIN OUTCOMES: Confirmed COVID-19 virus infection using Polymerase chain reaction (PCR) test is the primary outcome. The time period for measuring the primary outcome is any infection within the trial period up to one month after taking the last dose. RANDOMISATION: The randomized block allocation method was developed using Stata version 15 software by an independent researcher, using a block size of six. Allocation to the two treatment groups will be conducted by this researcher using paper labels (random 10-digit codes) in a 1:1 ratio t The labels will be attached to the drug packages in order of randomization. Drug packages will be arranged in a box according to the randomization list. BLINDING (MASKING): Participants and caregivers are blinded to group assignment and the data will be analyzed by an independent statistical expert who is unaware of the treatment allocation. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 282 participants will be randomised with 141 participants the Hydroxychloroquineeach intervention group and 141 participants to the placebo control group TRIAL STATUS: The protocol version number is 99-1-101-47091 and the approval ID is IR.TUMS.VCR.REC.1399.001 and recruitment began April 7, 2020, and is anticipated to be complete by August 7, 2020. TRIAL REGISTRATION: The name of the trial register is Iranian registry of clinical trial (IRCT), registration number is IRCT20120826010664N6, date of trial registration is April 7, 2020, FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Pirjani R, Soori T, Dehpour AR, et al. Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 32493447. doi:10.1186/s13063-020-04439-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。